It is the first nonhormonal treatment for the menopause symptom.
Category: Food and Drug Administration
-
FDA Ends Ban on Blood Donations From Gay and Bisexual Men
A new screening questionnaire would apply to all potential donors.
-
F.D.A. Advisers Say Benefits of Over-the-Counter Birth Control Pill Outweigh Risks
The agency is expected to decide this summer whether to allow the first nonprescription sales of an oral contraceptive in the United States.
-
F.D.A. Advisers Weigh Allowing First U.S. Over-the-Counter Birth Control Pill
The panel heard strong support from the company and many doctors but concern from F.D.A. scientists.
-
F.D.A. Approves Drug for Rare Form of A.L.S.
The drug, which will be sold as Qalsody by the pharmaceutical company Biogen, targets a genetic cause of a devastating neurological illness.
-
Sacklers Gave Millions to Institution That Advises on Opioid Policy
Even as the nation’s drug crisis mounted, the National Academies of Sciences, Engineering and Medicine continued to accept funds from some members of the Sackler family, including those involved with Purdue Pharma.
-
Abortion Pill Maker Sues F.D.A. to Protect Drug if a Court Orders It Off the Market
The suit by GenBioPro, the generic maker of mifepristone, is the latest strand in the intense legal battle over abortion pills.
-
What Bank Earnings Reveal About the Health of the Economy
JPMorgan Chase and Wells Fargo reported solid earnings on Friday, but big questions remain about the sector’s health and a potential recession.
-
Earnings Season Arrives With Recession Fears Front and Center
Investors will be closely watching whether worries about an economic slowdown dent corporate profits, and lead to further layoffs.
-
Appeals Court Says Abortion Pill Can Remain Available but Imposes Temporary Restrictions
The judges blocked the drug from being sent to patients through the mail and rolled back other steps the government had taken to ease access.
-
Juul Reaches $462 Million Settlement With New York, California and Other States
The case ends major litigation over claims of marketing e-cigarettes to adolescents, resolving thousands of lawsuits and amounting to billions of dollars in payouts to states, cities and people.